与局部晚期直肠癌的新辅助化疗相比,新辅助化疗和新辅助化疗的短期和长期结果:更新的元分析
Yue Guo1, Zhifeng Guo2, Jiaojiao Zhang3
1Department of Anorectal Branch, Nanyang Central Hospital, Nanyang, 473005, China.
BMC gastroenterology
|February 18, 2025
概括
新辅助化疗 (NAC) 与局部晚期直肠癌 (LARC) 的新辅助化疗 (NACRT) 提供类似的结果. 对于高风险的LARC患者,需要对NAC与NACRT疗效进行进一步的研究.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
背景情况:
- 新辅助化学放射治疗 (NACRT) 是局部晚期直肠癌 (LARC) 的标准,但会导致毒性.
- 新辅助化疗 (NAC) 是NACRT的一个新兴替代方案.
- 优化化疗方案可能会提高NAC的疗效.
研究的目的:
- 在LARC患者中比较NAC与NACRT的短期和长期结果.
- 评估NAC和NACRT的瘤和毒性概况.
- 为了为LARC管理的治疗决策提供信息.
主要方法:
- 10项研究的元分析,包括14807名LARC患者.
- 综合了符合资格研究的短期和长期结果.
- 在线数据库中搜索到2023年6月15日之前发表的研究.
主要成果:
- 淋巴血管侵袭,围神经侵袭,R0切除,局部复发,存活率或3-4级不良事件没有显著差异.
- NAC组显示出较低的病理完整反应和瘤回归,但关节保存率更高.
- 前性研究发现,病理完整反应,瘤回归或关节保存没有显著差异.
结论:
- NAC实现了与LARC的NACRT相似的短期和长期结果.
- 高风险的LARC患者需要进一步调查NAC与NACRT疗效.
- NAC可能是NACRT的一个可行的替代品,在关节的保护方面具有潜在的好处.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
173
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
173


